CoChat

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Open access
Stroes, Erik, Guyton, John R., Lepor, Norman, Civeira, Fernando, Gaudet, Daniel, Watts, Gerald F., Baccara‐Dinet, Marie T., Lecorps, Guillaume, Manvelian, Garen, Farnier, Michel, Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., Hoag, G., Hove, J., Jeppesen, J., Kjærulf, J.H., Klarlund, K., Thomsen, K.K., Basart, D.C.G., Kooy, A., Liem, A., Swart, H., Troquay, R., Van Het Hof‐Wiersma, J, Viergever, P., Visseren, F., Doughty, R.N., Scott, R., Calvo, C., Díaz‐Díaz, J.L., Fuentes, F., Gil‐Extremera, B., Jericó, C., Matas Pericas, L., Mediavilla Garcia, J.D., Bolster, D.E., Koren, M., El Shahawy, M., Vardi, G., Weinstein, D., Zuzarte, K., Ginsberg, Henry, Robinson, Jennifer G., Rader, Daniel J., Cannon, Christopher P., Colhoun, Helen, Kastelein, John J.P., Huo, Yong, Olsson, Anders, Waters, David, Larrey, Dominique, Rosenson, Robert S., Patriarca, Peter A., Molenberghs, Geert, Tricoci, Pierluigi, Mahaffey, Kenneth W., Lopes, Renato D., Shah, Bimal R., Mehta, Rajendra H., Roe, Matthew T., Eapen, Zubin, Armaganijan, Luciana, Bertolami, Adriana, Leonardi, Sergio, Kolls, Bradley J., Jordan, J. Dedrick, Ducrocq, Grégory, Puymirat, Etienne, Mathews, Robin · 2016 · Journal of the American Heart Association
Cited by 102

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: The PCSK 9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol ( LDL ‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin‐associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone. Methods and Results: Patients were randomly assigned to placebo, alirocumab 150 mg Q4W or 75 mg Q2W (calibrator arm), with dose adjustment to 150 mg Q2W at week (W) 12 if W8 predefined LDL ‐C target levels were not met. The primary efficacy endpoint was LDL ‐C percentage change from baseline to W24. Mean baseline LDL ‐C levels were 163.9 mg/dL (alirocumab 150 mg Q4W, n=59), 154.5 mg/dL (alirocumab 75 mg Q2W, n=116), and 158.5 mg/dL (placebo, n=58). In the alirocumab 150 mg Q4W and 75 mg Q2W groups (49.1% and 36.0% of patients received dose adjustment, respectively), least‐squares mean LDL ‐C changes from baseline to W24 were −51.7% and −53.5%, respectively (placebo [+4.7%]; both groups P <0.0001 versus placebo). In total, 63.9% and 70.3% of alirocumab‐treated patients achieved their LDL ‐C targets at W24. Treatment‐emergent adverse events occurred in 77.6% (alirocumab 150 mg Q4W), 73.0% (alirocumab 75 mg Q2W), and 63.8% (placebo) of patients, with injection‐site reactions among the most common treatment‐emergent adverse events. Conclusions: Alirocumab 150 mg Q4W can be considered in patients not on statin with inadequately controlled hypercholesterolemia as a convenient option for lowering LDL ‐C. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02023879.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.116.003421

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 102

Metadata

Authors
Stroes, E., Guyton, J. R., Lepor, N., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G., Farnier, M., Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., Hoag, G., Hove, J., Jeppesen, J., Kjærulf, J. H., Klarlund, K., Thomsen, K. K., Basart, D. C. G., Kooy, A., Liem, A., Swart, H., Troquay, R., Van Het Hof‐Wiersma, J., Viergever, P., Visseren, F., Doughty, R. N., Scott, R., Calvo, C., Díaz‐Díaz, J. L., Fuentes, F., Gil‐Extremera, B., Jericó, C., Matas Pericas, L., Mediavilla Garcia, J. D., Bolster, D. E., Koren, M., El Shahawy, M., Vardi, G., Weinstein, D., Zuzarte, K., Ginsberg, H., Robinson, J. G., Rader, D. J., Cannon, C. P., Colhoun, H., Kastelein, J. J. P., Huo, Y., Olsson, A., Waters, D., Larrey, D., Rosenson, R. S., Patriarca, P. A., Molenberghs, G., Tricoci, P., Mahaffey, K. W., Lopes, R. D., Shah, B. R., Mehta, R. H., Roe, M. T., Eapen, Z., Armaganijan, L., Bertolami, A., Leonardi, S., Kolls, B. J., Jordan, J. D., Ducrocq, G., Puymirat, E., & Mathews, R.
Venue
Journal of the American Heart Association
Published
2016-09
Volume
5
Issue
9
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2518726365
Cited by
102
References
15
FWCI
15.60
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. https://app.cochat.ai/papers/10.1161/jaha.116.003421
The paper
Stroes, E., Guyton, J. R., Lepor, N., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G., Farnier, M., Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., . . . Mathews, R. (2016). Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.116.003421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.